Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2025-12-17 Proxy Solicitation & In…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (EGM) for Immunovia AB. It outlines the meeting agenda, procedures for shareholder participation, proxy information, and specific proposals to be voted on, such as an amendment to the Articles of Association and a reverse share split. This document serves as the official solicitation and informational material provided to shareholders to prepare them for the upcoming meeting, which falls under the category of Proxy Solicitation & Information Statement.
2025-12-17 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Kallelse till extra bolagsstämma' (Notice of Extraordinary General Meeting) for Immunovia AB. It outlines the agenda, proposals for board decisions (such as share consolidation and articles of association changes), and instructions for shareholder participation. This document is a solicitation of shareholder action and information for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-12-17 Swedish
Styrelsen för Immunovia föreslår en sammanläggning av aktier
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from the Board of Directors of Immunovia AB regarding a proposed reverse stock split (1:100). It details the rationale, the impact on share count and par value, and provides an indicative timeline for the upcoming Extraordinary General Meeting (EGM) to approve the proposal. Since this relates to a change in capital structure (share consolidation), it falls under the 'Share Issue/Capital Change' category.
2025-12-17 Swedish
The Board of Directors of Immunovia proposes a reverse share split
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from the Board of Directors of Immunovia regarding a proposed reverse share split (1:100 ratio). It details the rationale, the impact on share count and quota value, and provides an indicative timetable for the process. This falls under the category of capital structure changes, specifically share consolidation/splits, which is classified as 'Share Issue/Capital Change' (SHA).
2025-12-17 English
Ändring av antalet aktier och röster i Immunovia AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding a change in the total number of shares and votes in Immunovia AB (publ) following a rights issue and a directed share issue. This type of regulatory disclosure, specifically concerning changes in share capital and voting rights, falls under the category of share issues and capital changes.
2025-11-28 Swedish
Change in number of shares and votes in Immunovia AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document explicitly announces a change in the number of shares and votes in Immunovia AB due to a rights issue and a directed issue of shares. This falls under the category of capital changes and share issuance announcements. According to the provided definitions, 'SHA' is the appropriate code for announcements regarding new share issues or capital changes.
2025-11-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.